India’s pharmaceutical sector is moving toward proprietary drug discovery, with R&D funding reaching $731 million in FY26. While patent filings and biotech startups are increasing, the industry faces challenges in matching global clinical trial scale and R&D spending. This shift aims to move companies up the value chain from cost-effective generic manufacturing to high-value intellectual property creation.
Detailed Coverage
For decades, the Indian pharmaceutical industry earned its reputation as the 'world's pharmacy' by mastering the production of affordable, high-quality generic drugs. However, a significant strategic pivot is now underway. Domestic companies are increasingly moving beyond manufacturing existing medicines toward the complex, high-risk, and high-reward domain of novel drug discovery and proprietary technology platforms.
Scaling the Innovation Pipeline
Data indicates this transition is gaining momentum. In the last decade, patent filings within India’s life sciences sector have increased more than fourfold. This shift is supported by a growing ecosystem of biotech startups, which have expanded to approximately 2,400. Financial backing is also following this trend, with private equity and venture capital funding for pharmaceutical research and development climbing to $731 million in FY26. Companies are looking to move up the value chain, focusing on global licensing and the creation of intellectual property to secure a larger share of the global pharmaceutical market.
The Hurdles of Novel Drug Development
Investors should note that moving from generic production to novel therapy discovery introduces a different risk profile. Developing a new drug is a capital-intensive process that spans molecule discovery, preclinical testing, and extensive human clinical trials. Unlike the predictable revenue models associated with generic drug manufacturing, novel drug development involves years of heavy capital spending with no guarantee of regulatory approval or commercial success. The success of this transition will depend heavily on the ability of Indian firms to execute clinical trials efficiently and secure approvals from international regulators like the U.S. FDA.
Assessing India’s Competitive Position
While the sector is evolving, a significant gap remains compared to global leaders. Current annual R&D spending in India, estimated at $2 billion to $3 billion, remains a small fraction of the $70 billion to $75 billion invested by the United States. Furthermore, while India accounts for nearly 15% of the global disease burden, it currently conducts only 4% of the world's clinical trials. To succeed, the sector must bridge this gap, improve the commercial quality of its patent filings, and deepen the technical expertise among local venture capital investors, who currently have less biotech-specific experience compared to their American counterparts.
Monitoring Future Progress
Several Indian companies have already begun demonstrating their capabilities. Success stories such as Zydus’ NASH drug, Glenmark’s licensing agreement with AbbVie, and Wockhardt’s FDA-approved antibiotic Zaynich highlight the industry's potential to produce commercially viable novel assets. Looking ahead, investors should track how effectively government-backed programs like the National Biopharma Mission and institutional support from hubs like Genome Valley translate into scalable, profitable medicine. The key monitorable for the industry will be the successful commercialization of these novel assets and the ability to maintain cost efficiency while scaling complex R&D operations.